Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Biochemical Pharmacology

• Publication date

  2002-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0006-2952(02)01261-3PMID 12234611
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen‐specific cytotoxic T‐cell function

  2001cited by this paper
• Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.

  2001cited by this paper
• Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.

  2001cited by this paper
• Cloning and characterization of a histone deacetylase, HDAC9

  2001cited by this paper
• Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment

  2000cited by this paper
• Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.

  2000cited by this paper
• Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways.

  2000cited by this paper
• Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

  2000cited by this paper
• Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites

  2000cited by this paper
• Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all‐trans retinoic acid

  2000cited by this paper
• Transcription Factor ZBP-89 Cooperates with Histone Acetyltransferase p300 during Butyrate Activation of p21 waf1 Transcription in Human Cells*

  2000cited by this paper
• p300 Collaborates with Sp1 and Sp3 in p21 waf1/cip1 Promoter Activation Induced by Histone Deacetylase Inhibitor*

  2000cited by this paper
• differentiation and cell cycle arrest in U-937 monoblasts induced − Phosphorylation-deficient Stat 1 inhibits retinoic acid

  2000cited by this paper
• Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor.

  1999cited by this paper
• Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy

  1999cited by this paper
• Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects*

  1999cited by this paper
• Cloning of a GADD34-like gene that interacts with the zinc-finger transcription factor which binds to the p21(WAF) promoter.

  1999cited by this paper
• Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1

  1999cited by this paper
• A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

  1999cited by this paper
• FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

  1998cited by this paper
• Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells

  1998cited by this paper
• Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia

  1998cited by this paper
• Role of the histone deacetylase complex in acute promyelocytic leukaemia

  1998cited by this paper
• Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein

  1998cited by this paper
• Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

  1998cited by this paper
• Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL

  1998cited by this paper
• Effects of p21Cip1/Waf1 at Both the G1/S and the G2/M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication

  1998cited by this paper
• Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

  1998cited by this paper
• Histone acetylation in chromatin structure and transcription

  1997cited by this paper
• Butyrate Activates the WAF1/Cip1 Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line*

  1997cited by this paper
• The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells.

  1997cited by this paper
• Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.

  1997cited by this paper
• Human tumor models in the severe combined immune deficient (scid) mouse

  1997cited by this paper
• Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone‐dependent transcriptional repression

  1997cited by this paper
• The CBP co-activator is a histone acetyltransferase

  1996cited by this paper
• The transcriptional coactivators p300 and CBP are histone acetyltransferases.

  1996cited by this paper
• Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells.

  1996cited by this paper
• Repression and activation by multiprotein complexes that alter chromatin structure.

  1996cited by this paper
• p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation.

  1995cited by this paper
• p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells

  1995cited by this paper
• Treatment of Philadelphia‐chromosome‐positive human leukemia in scid mouse model with herbimycin A, bcr‐abl tyrosine kinase activity inhibitor

  1995cited by this paper
• Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells.

  1995cited by this paper
• Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient.

  1994cited by this paper
• Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.

  1994cited by this paper
• FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.

  1994cited by this paper
• Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines.

  1994cited by this paper
• Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells.

  1994cited by this paper
• FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.

  1994cited by this paper
• Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

  1993cited by this paper
• Butyric acid and its monosaccharide ester induce apoptosis in the HL-60 cell line.

  1993cited by this paper
• A positive role for histone acetylation in transcription factor access to nucleosomal DNA.

  1993cited by this paper
• Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

  1993cited by this paper
• Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits.

  1993cited by this paper
• Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.

  1992cited by this paper
• p52(PAI-1) and actin expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells.

  1991cited by this paper
• Membrane Proteins Involved in Phagocyte Adherence to Endothelium

  1990cited by this paper
• Control of HL-60 monocytic differentiation. Different pathways and uncoupled expression of differentiation markers.

  1987cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies.

  1983cited by this paper
• Terminal differentiation surface antigens of myelomonocytic cells are expressed in human promyelocytic leukemia cells (HL60) treated with chemical inducers.

  1981cited by this paper

• TET1 Functions as an Oxidized LDL Dependent Early-Stage Inducer of Atherosclerosis by Initiating Foam Cell Formation in Macrophages

  2026cites this paper
• Marine peptides in lymphoma: surgery at molecular level for therapeutic understanding

  2025influential citation
• Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor Romidepsin using Poly-(D,L-lactide-co-glycolide) nanoparticles as a drug carrier.

  2025cites this paper
• Pathologic HDAC1/c-Myc signaling axis is responsible for angiotensinogen transcription and hypertension induced by high-fat diet.

  2023cites this paper
• Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma

  2022cites this paper
• Effect of the HDAC Inhibitor on Histone Acetylation and Methyltransferases in A2780 Ovarian Cancer Cells

  2021cites this paper
• Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3

  2021cites this paper
• Identification of novel candidate genes and small molecule drugs in ovarian cancer by bioinformatics strategy

  2021cites this paper
• Synthesis and Biological Evaluation of a Depsipeptidic Histone Deacetylase Inhibitor via a Generalizable Approach Using an Optimized Latent Thioester Solid-Phase Linker.

  2020cites this paper
• An Overview of HDAC Inhibitors and their Synthetic Routes.

  2019cites this paper
• Inhibition of class I HDACs attenuates renal interstitial fibrosis in a murine model

  2019cites this paper
• Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells

  2017cites this paper
• Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c‐Jun/caspase3 pathway in hepatocellular carcinoma cells

  2017cites this paper
• HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.

  2017cites this paper
• Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study

  2017cites this paper
• IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer

  2016cites this paper
• Butyrate production from high-fiber diet protects against lymphoma tumor

  2016cites this paper
• FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.

  2016cites this paper
• Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms

  2016cites this paper
• Epigenetic inhibitors.

  2015cites this paper
• Histone deacetylase inhibitors: potent anti-leukemic agents.

  2015cites this paper
• Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.

  2015cites this paper
• Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis

  2015cites this paper
• Romidepsin for the treatment of non-Hodgkin’s lymphoma

  2015cites this paper
• Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma

  2015cites this paper
• Cancer Epigenetics

  2015cites this paper
• Histone Deacetylase Inhibitor as a Novel Anticancer Agent: A Review

  2015cites this paper
• Therapy of Cancer Mediated by Histone Deacetylase Inhibitor Deacetylase Inhibitors by In Vivo Molecular Imaging and for Transcription Targeting P 21-Driven Multifusion Gene System for Evaluating the Efficacy of Histone

  2014cites this paper
• Inhibiteurs de hdac pour supprimer la cachexie liée au cancer

  2014cites this paper
• P21-Driven Multifusion Gene System for Evaluating the Efficacy of Histone Deacetylase Inhibitors by In Vivo Molecular Imaging and for Transcription Targeting Therapy of Cancer Mediated by Histone Deacetylase Inhibitor

  2014cites this paper
• Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors

  2013cites this paper
• Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors

  2013cites this paper
• A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

  2012cites this paper
• Low‐dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T‐cell lymphoma lesions

  2012cites this paper
• Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas

  2012cites this paper
• The role of angiogenesis inhibitors in the management of melanoma.

  2012cites this paper
• Histone deacetylase inhibitors as a tool to up-regulate new fungal biosynthetic products: isolation of EGM-556, a cyclodepsipeptide, from Microascus sp.

  2011cites this paper
• Emerging role of epigenetic therapies in cutaneous T-cell lymphomas

  2010cites this paper
• Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

  2010cites this paper
• Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

  2010cites this paper
• Perspectives in drug development for metastatic renal cell cancer

  2010cites this paper
• FK228 induces mitotic catastrophe in A549 cells by mistargeting chromosomal passenger complex localization through changing centromeric H3K9 hypoacetylation.

  2010cites this paper
• Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in vitro and in vivo.

  2010cites this paper
• Epigenomics and ovarian carcinoma.

  2010cites this paper
• Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.

  2010cites this paper
• FK 228 induces mitotic catastrophe in A 549 cells by mistargeting chromosomal passenger complex localization through changing centromeric H 3 K 9 hypoacetylation

  2010cites this paper
• Curcumin-induced histone acetylation in malignant hematologic cells

  2009cites this paper
• Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

  2009cites this paper
• Expression and Function of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts

  2009cites this paper
• Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.

  2009cites this paper
• Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.

  2009cites this paper
• Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.

  2008cites this paper
• Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.

  2008cites this paper
• Histone deacetylase inhibitors: new hope for rheumatoid arthritis?

  2008cites this paper
• Smenospongine, a Sesquiterpene Aminoquinone from a Marine Sponge, Induces G1 Arrest or Apoptosis in Different Leukemia Cells

  2008cites this paper
• Effect of depsipeptide on in vitro transfection efficiency of PEI/DNA complexes.

  2008cites this paper
• Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC Inhibitors—Nanomolar‐Potency Inhibitors of Pancreatic Cancer Cell Growth

  2008cites this paper
• Roles of Cytoplasmic Deacetylase Hdac6 in Oncogenic Tumorigenesis

  2008cites this paper
• A work in progress: The clinical development of histone deacetylase inhibitor

  2008cites this paper
• Antimalarial Activity of Phenylthiazolyl-Bearing Hydroxamate-Based Histone Deacetylase Inhibitors

  2008cites this paper
• Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.

  2008cites this paper
• New treatment concepts in diffuse large B-cell lymphomas (DLBL): chemothe-rapy and biological therapy.

  2007cites this paper
• Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.

  2007cites this paper
• Histone deacetylase inhibitors in cancer therapy

  2007cites this paper
• Clinical Significance of Histone Deacetylase Inhibitors in Cancer

  2007cites this paper
• Inhibitory Effects of Histone Deacetylase Inhibitor Depsipeptide on Benzo(a)pyrene- and Cyclophosphamide-Induced Genotoxicity in Swiss Albino Mice

  2007cites this paper
• Histone deacetylase inhibitors: molecular mechanisms of action

  2007cites this paper
• Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).

  2007cites this paper
• Vitamin d and its role in cancer and immunity: a prescription for sunlight.

  2007cites this paper
• Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies.

  2007cites this paper
• Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines

  2006cites this paper
• Highlights From: 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10–13, 2005

  2006cites this paper
• The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.

  2006cites this paper
• 47th Annual Meeting of the American Society of Hematology Atlanta, GA.

  2006cites this paper
• Vitamin D compounds: activity against microbes and cancer.

  2006cites this paper
• JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model.

  2006cites this paper
• Histone deacetylase inhibitors as potent modulators of cellular contacts.

  2006cites this paper
• Histone Deacetylase Inhibitor FK228 Activates Tumor Suppressor Prdx1 with Apoptosis Induction in Esophageal Cancer Cells

  2005cites this paper
• Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.

  2005cites this paper
• Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228

  2005cites this paper
• Proteomic profiling of mature CD10+ B-cell lymphomas.

  2005cites this paper
• Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.

  2005cites this paper
• Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review

  2005cites this paper
• Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer

  2005cites this paper
• New anti-cancer strategies: epigenetic therapies and biomarkers.

  2005cites this paper
• Clinical Pharmacology of MS-275, A Histone Deacetylase Inhibitor

  2005cites this paper
• Histone Deacetylase Inhibitor FK 228 Activates Tumor Suppressor Prdx 1 with Apoptosis Induction in Esophageal Cancer Cells

  2005cites this paper
• Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

  2005cites this paper
• Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.

  2005cites this paper
• Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.

  2005cites this paper
• Differential Effects of Histone Deacetylase Inhibitors in Tumor and Normal Cells—What Is the Toxicological Relevance?

  2005cites this paper
• Vitamin D compounds in leukemia.

  2005cites this paper
• Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance

  2005cites this paper
• Role of histone deacetylase inhibitors in the treatment of cancer (Review).

  2004cites this paper
• Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor.

  2004cites this paper
• Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1‐containing fusion proteins

  2004cites this paper
• Histone deacetylase inhibitors in clinical development

  2004cites this paper
• A Clue to the Therapy of Neurofibromatosis Type 2: NF2/Merlin Is a PAK1 Inhibitor

  2004cites this paper
• The epigenetics of ovarian cancer drug resistance and resensitization.

  2004cites this paper
• Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.

  2004cites this paper